E10030 (Aptamer) - Wet AMD Intravitreal

One of them is E10030 (Ophthotech), an anti-platelet-derived growth factor (anti-PDGF-B) aptamer. E10030 strongly binds to PDGF-B.

PDGF-B plays a key role in recruiting the pericytes that envelop the new vessels and make them more resistant to the anti-VEGF attack.

In combination with anti-VEGF, this new agent could represent a breakthrough therapy.

A phase I study⁽¹⁴⁾ with an intravitreal anti-platelet-derived growth factor (PDGF) aptamer that targets pericytes, was evaluated in combination therapy with ranibizumab (Lucentis^®, Genentech) in patients with neovascular age-related macular degeneration (AMD) with promising results regarding safety and efficacy⁽¹⁵⁾.